In patients with poor-risk relapse of aggressive lymphoma, reduced-intensity conditioning followed by allogeneic PBSCT may have its limitations because of rapid regrowth of the tumor. We tried to address this problem by intermediate-intensity conditioning followed by allogeneic SCT.
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Patients with lymphoma progressing under primary therapy, or with relapse and poor-risk features, represent a therapeutic challenge. Cytotoxic drugs or radiation as well as high-dose therapy fol1owed by autologous hematopoietic stem cell transplantation (ASCT) were shown to induce further clinical remissions, but long-term outcome was generally poor. 1, 2 Allogeneic stem ce11 transplantation (allo PBSCT) may exert a graft-versus-lymphoma (GVL) effect and thus contribute to disease control. Allogeneic SCT, however, was found associated with high treatmentrelated mortality (TRM), mainly due to the toxicity of the conditioning regimen and the occurrence of GVHD. 3, 4 Nonmyeloablative conditioning (NST) has attracted interest in lymphoma patients as a means to reduce TRM in allogeneic transplantation. [5] [6] [7] [8] In some studies, NST has been used together with T-cell depleting antibodies like ATG or a1emtuzumab in order to reduce both GVHD and TRM. 9 As T-cell depletion compromises the GVL effect, delayed infusion of donor leukocytes (DLI) has been proposed to restore T-ce11 function and induce GVL. 10 We used a conditioning regimen of reduced intensity (fludarabine, busulfan, cyclophosphamide) prior to alloPBSCT. In a first cohort of patients with aggressive NHL, grafts were depleted from T lymphocytes by ex vivo CD34 þ selection of stem cells and in vivo application of anti-lymphocyte globulin (ALG). DLI were given in case of disease progression. In a second cohort of patients, the conditioning regimen without ATG was fol1owed by transplantation of unmanipu1ated PBSC grafts and cyclosporine A (CSA) and mycophenolat mofetil (MMF) as GVHD prophylaxis. 11 The outcome dramatically improved after CD34 þ selection, and in vivo T-cell depletion was abandoned underscoring the importance of an early GVL effect in patients with aggressive lymphoma.
Patients and methods

Eligibility criteria and patient characteristics
From November 1999 to March 2003, 21 consecutive patients with a diagnosis of aggressive/rapidly growing lymphoma, below 60 years of age and fulfilling one of the following criteria were included in a program of allogeneic PBSCT: (1) primary progression under therapy; (2) early relapse (o12 months) after primary conventional therapy; (3) relapse after HDT and ASCT. The first 10 patients received GVHD prophylaxis with CD34 þ selection, ALG and short-course CSA (see below). When early relapse emerged as a serious problem with this treatment, CD34 þ selection was abandoned and GVHD prophylaxis was changed to CSA plus MMF, which was given to the next 11 patients. Most patients included had a diagnosis of diffuse large B-cell lymphoma. Single patients with lymphoblastic lymphoma/ALL, blastic mantle cell lymphoma, Hodgkin's disease or follicular lymphoma histologic grade 3 were also included. All patients belonged to a high-risk population regarding both treatment-related toxicity and relapse probability. There were no significant differences between both groups for known risk factors as the number of prior treatment regimens, percentage of patients with prior HDT, chemoresistant disease at transplant or age (see Table 1 ). Age-adjusted IPI score immediately prior to transplant showed a tendency to be higher in the second cohort of patients but this difference did not reach the level of statistical significance (P ¼ 0.08, Mann-Whitney test).
Conditioning regimen, transplant characteristics and GVHD-prophylaxis
All patients received a conditioning regimen consisting of fludarabine (total dose 125 mg/m 2 ; 25 mg/m 2 /day from day À11 to À7 in group 1, day À8 to day À4 in group 2), busulfan (total dose 12 mg/kg p.o. or 9.6 mg/kg i.v, respectively; 3.2 mg/kg/day i.v. in group 1; 4 mg/kg/day orally in group 2 from day À6 to day À4) and cyclophosphamide (total dose 120 mg/kg; 60 mg/kg/day day À3 and day À2). The day of transplantation was designated as day 0. Stem cells were mobilized with G-CSF from genotypically HLA-matched family or unrelated donors (MUD). The number of CD34 þ cells transplanted was similar in both groups with a median of 4.8 Â 10 6 /kg BW (range 2.6-10.5) in group 1 and 4.5 Â 10 6 /kg BW (range 3.0-14.0) in group 2, respectively. HLA-identical siblings served as the donor in similar proportions of patients in both groups (3/10 vs 4/11 patients). In group 1, one patient received a haplo-mismatched transplant from a family donor. All other patients received MUD transplants. Filgrastim was administered at a dose of 5 mg/kg BW from day þ 5 until recovery of leukocytes above 1/nl to all patients. In the first group of patients, GVHD prophylaxis was attempted by CD34 þ selection of stem cells with the Clinimacs s system (Miltenyi Biotec, Bergisch-Gladbach, Germany). In addition, ALG (Imtix-SangStat GmbH, Ketsch, Germany) was given at doses of 5 mg/kg/day from day À4 to day À2, CSA was added from day À1 to day þ 28 after transplantation. In group 2, GVHD prophylaxis consisted of CSA from day À1 until day þ 100 and MMF from day þ 1 to day þ 28. No graft manipulation was performed. If no GVHD occurred until day þ 28, CSA was tapered. If acute GVHD (aGVHD) Xgrade II was observed, MMF was continued beyond day þ 28 and steroid treatment was started. One patient in group 2 received the anti-TNF alpha antibody infliximab for treatment of intestinal GVHD, grade IV. Short-tandem repeat PCR followed by Genescan analysis was used for estimation of donor chimerism. This method was able to detect at least 5% of donor cells in a majority of recipient cells. Chimerism analysis in peripheral blood was performed at least once after recovery of leukocytes in group 1 and on a regular basis at days þ 14, þ 28, þ 56 and þ 100 in group 2.
Statistical methods
The Kaplan-Meier method was used for description and analysis of survival data. Surviving patients were censored at last day of follow up. Comparison of groups was carried out by the log-rank test. The Cox regression method was used for multivariate analysis. All analyses were performed by Statistica software package version 6.1.188.0 (StatSoft, Tulsa, OK, USA). 
Results
Hematopoetic recovery and engraftment
Recovery of leukocytes was rapid in both groups. The median time to reach more than 1 leukocyte/nl was 10 days (range: 10-11 days) in group 1 and 11 days (range: 9 to 14 days) in group 2. More than 20 platelets (plt)/nl were reached on day 15 (range: 7-29 days) in group 1 and on day 12 (range: 6-59 days) in group 2. Platelet transfusion policy was identical in both groups (trigger value: 20 plt/nl). The median number of platelet transfusions until recovery was 18 (range: 3-35) in group 1 and 4 (range: 1-12) in group 2, respectively. However, platelets were provided by different blood banks, which makes direct comparison of transfusion numbers difficult. Donor type chimerism in peripheral blood after leukocyte recovery exceeded 95% in all patients of group 1. In group 2, chimerism analysis was carried out at defined time points after alloSCT. More than 95% donor type chimerism was found as early as day þ 14 in all patients of group 2. No cases of secondary graft failures were observed.
TRM, organ toxicity, infectious complications and GVHD
Four cases of TRM were observed (Table 2) . One patient died due to toxic pneumonitis, one died due to venoocclusive disease (VOD). In two cases, pneumonia was the leading cause of death. In a fifth patient, the cause of death could not be determined. This patient had a blastic mantle cell lymphoma with leukemic evasion immediately prior to alloSCT. Shortly after SCT, fever and progressive central failure of respiration were observed. A CT scan revealed multiple cerebral lesions. A definitive discrimination between intracerebral lymphoma or infection (toxoplasmosis, aspergillosis) was not possible. The patient died at day þ 114 post-SCT. There were no cases of oral mucosa damage 4 grade II WHO in patients of both groups, and the majority of patients did not need complete parenteral nutrition. Patients of group I showed no signs of relevant hepatic toxicity or VOD. Four out of 21 patients did not develop fever above 38.01C in the early post transplant period. The median number of days with fever was 3 in group 1 (range 0-16) and 2 in group 2 (range 0-17). Prior to DLI, aGVHD was not observed in group 1. Six out of 10 patients received at least one donor leukocyte infusion after alloSCT. In three of them, this was followed by significant aGVHD (Xgrade 2). In contrast, patients in group 2 had a significant risk of aGVHD. Six of them developed GVHD Xgrade 2 and 3 of them had aGVHD grade III-IV. DLI were not performed in this second group of patients.
Relapse and survival
In group 1, all patients not dying early due to TRM progressed very rapidly. Within 6 months after transplant, all surviving patients had relapsed and all but one patient died due to progression of lymphoma. The only survivor had slowly progressive Hodgkin's disease. He received a donor lymphocyte infusion, developed aGVHD grade II, and subsequently chronic GVHD. At the time of this analysis, he is alive with stable disease 39 months after transplant. In contrast, eight of nine surviving patients from group 2 were progression free after a median observation time of 10.5 months. One patient showed progression on CT scan 13 months after SCT. He has stable disease after discontinuation of immunosuppressive therapy. Overall survival rate at 1 year was 79.6 vs 10 % (P ¼ 0.0048, log rank test) (Figure 1 ). In this small cohort of patients, univariate analysis could not identify any of the following parameters as a significant risk factor for survival: age at transplant, chemoresistant disease prior to alloSCT, prior HDT, number of prior regimens, ageadjusted IPI score prior to transplant or MUD transplant, respectively. Prior HDT (Figure 2a) and three or more lines of previous therapy (Figure 2b ) had the strongest impact on survival in our patients. A multivariate Cox regression model using these two variables and modality of GVHD prophylaxis (group 1 vs group (2) identified only intensive GVHD prophylaxis by CD34 þ selection (group 1) as significant risk factor for survival (P ¼ 0.014).
Discussion
High-dose therapy followed by ASCT is an effective treatment for relapsed aggressive non-Hodgkin's lymphoma 12 and Hodgkin's disease. 13 However, patients with primary progressive disease, early or, chemorefractory relapse or failure after prior high-dose therapy rarely achieve long-lasting remissions with ASCT.
1,2,14-17 Allogeneic transplantation is increasingly being offered to such patients in order to exploit a potential GVL effect associated with such treatment. 18, 19 However, evidence of a GVL effect in patients with poor-risk aggressive NHL and HD is limited, and TRM after myeloablative conditioning and allogeneic transplantation for these disorders has been unacceptably high. The use of reduced-intensity conditioning (RIC) has been recommended to circumvent this problem. While initial reports confirm lower TRM after RIC, de-escalation of drug doses used for conditioning prior to allogeneic transplantation carries the risk of higher relapse rates especially in rapidly growing tumors like poor-risk aggressive NHL. 8 We sought to design a treatment protocol that allowed for effective tumor control by administration of fludarabine together with busulfan and cyclophosphamide at doses not far below those doses used in standard conditioning regimens followed by allogeneic transplantation of peripheral blood cells. The fact that busulfan has documented anti-lymphoma activity [20] [21] [22] but is not routinely used for treatment of patients with lymphoma was another reason to use this conditioning regimen. Engraftment was uniformly rapid and complete in all patients studied. Overall, TRM was in the range observed in most series of RIC. Nevertheless, two out of four patients died as a consequence of organ toxicity rather than GVHD or immune suppression and infection. In order to avoid GVHD and its associated toxicity, our first approach included T-cel1 depletion of the graft by CD34 þ selection and planned DLIs. While patients given CD34 þ selected stem cells indeed did not develop significant aGVHD, all of them relapsed very early after transplantation. DLIs induced GVHD in some cases, but no effect on the lymphoma was observed.
As a consequence, in a second cohort of patients, we changed our strategy of GVHD prophylaxis preserving the conditioning regimen and other details of the treatment protocol. Following the administration of CSA plus MMF for GVHD prophylaxis and infusion of unmanipulated PB grafts, most patients developed early and in some instances moderate to severe GVHD. In these patients, we observed a significantly better control of disease with nine out of 11 patients achieving CR/PR for a median observation time of 10.5 months. Although morbidity was substantially higher after transplantation of unmanipulated grafts, TRM did not significantly increase as compared to the previous (n ¼ 10) had a significantly worse outcome compared to patients receiving GVHD prophylaxis with MMF plus CSA (n ¼ 11, P ¼ 0.0048).
T cells and GVL effect in lymphoma B Glass et al cohort of patients who had received CD34 þ selected hematopoietic cells. Time to treatment failure and overall survival was significantly better in patients given unmanipulated stem cells.
Conclusions from this study are hampered by its retrospective design, small patient numbers and short follow up. However, the differences between both cohorts are so striking that some preliminary conclusions can be drawn.
This study strongly suggests that high numbers of donor T cells should be present early after transplantation to exert a clinically significant GVL effect. Infusion of donor T cells weeks or months after transplantation of CD34 þ selected stem cells was insufficient to induce clinical remissions in patients with fast growing tumors like poor-risk aggressive NHL. The frequent responses seen in patients with advanced lymphoma when given full allografts support Figure 2 (a) Survival after allogeneic PBSCT according to number of prior regimens. Patients with less than four different regimens of prior therapy (n ¼ 13) did not differ significantly from those receiving more than three different regimens (n ¼ 8, P ¼ 0.38). (b) Survival after allogeneic PBSCT in patients with prior high-dose therapy (n ¼ 13) vs patients without prior HDT (n ¼ 8). There was no significant difference in survival (P ¼ 0.14).
the existence of a clinically important GVL effect also in poor-risk aggressive lymphoma patients if T cells are given with the graft.
Juckett et al 23 reported a series of 37 patients with NHL, among them 21 patients with aggressive histologies receiving high-dose therapy followed by T-cell-depleted allogeneic grafts. Relapse rate in the 21 patients with aggressive lymphoma was 43 % and seems lower than reported in this analysis. However, the patients in the study of Juckett et al were clearly less heavily pretreated. Only four out of 21 patients had received more than two regimens prior to allogeneic transplant and none of them had had prior highdose therapy and autologous transplant. In contrast, 10 of our 21 patients had more than two regimens and 13 had received high-dose therapy and autologous SCT prior to allogeneic SCT. We used immunomagnetic CD34 þ selection for T-cell depletion, which is highly effective and usually results in more than three log depletion of T cells. Juckett et al used a monoclonal anti-T-cell antibody with a median depletion efficacy of 1.7 log. This less-pronounced T-cell depletion resulted in a higher incidence of aGVHD. One can speculate that the residual T cells exerted a GVL effect in their patients, and that the impact of GVL is more important in extremely pretreated patient populations as reported in our study.
Our observations are in line with those reported by Perez-Simon et al 24 , who compared the results of RIC with or without alemtuzumab in patients with lymphoma and related diseases transplanted in the UK and Spain. Alemtuzumab as a very effective means of in vivo T-cell depletion led to significantly less GVHD and TRM, but a GVL effect became obvious after DLI only in the majority of patients. In contrast to our patients, most patients reported in the British-Spanish study suffered from lowgrade NHL, CLL or MM. In these disorders with comparatively low proliferative activity, infusion of DLI was able to induce tumor responses in many patients. In patients with aggressive NHL and poor-risk features (refractory tumor, previous autograft, etc.), effective debulking of the tumor and transplantation of donor T cells together with the hematopoietic stem cells is necessary to harness tumor growth at a stage when the effector (T cell) to tumor cell ratio is still favorable and bulky disease has not already developed.
